Investigations required for the initial characterization and evaluation of women with GT
| Diagnostic parameters . | Role . |
|---|---|
| GT characterization | |
| Light transmission aggregometry | To confirm GT |
| Quantitative αIIbβ3 evaluation by flow cytometry and/or western blot | To classify GT subtype and evaluate the risk of anti-αIIbβ3 immunization |
| Genetic studies (ITGA2B/ITGB3) | To confirm GT, enable genetic counseling and prenatal diagnosis, and evaluate the risk of anti-αIIbβ3 immunization |
| Evaluation prior to pregnancy | |
| CBC (PLT, Hb, MCV), ferritinemia | To screen for anemia and iron deficiency |
| Previous history of PPH or other adverse pregnancy outcomes | To assess maternal and fetal/neonatal related risks |
| Recent platelets or RBC transfusion (<3-6 mo) | To assess the risk of recurrence or development of antiplatelet antibodies |
| Anti-HLA antibodies screening | To select treatment strategies, ensure efficacy, and anticipate tolerance of platelet concentrates administration |
| Anti-αIIbβ3 antibodies screening (MAIPA) | To select treatment strategies, ensure efficacy, and anticipate tolerance of platelet concentrates administration To evaluate the risk of fetal/neonatal thrombocytopenia |
| Oral and nasal clinical status | To assess needs and anticipate potential treatment needed to prevent further increase in gum- and nose-bleeding episodes during pregnancy |
| Fertility of couple | To evaluate the chances of obtaining pregnancy and avoid unnecessary exposure to heavy menstrual bleeding in case of infertility |
| Diagnostic parameters . | Role . |
|---|---|
| GT characterization | |
| Light transmission aggregometry | To confirm GT |
| Quantitative αIIbβ3 evaluation by flow cytometry and/or western blot | To classify GT subtype and evaluate the risk of anti-αIIbβ3 immunization |
| Genetic studies (ITGA2B/ITGB3) | To confirm GT, enable genetic counseling and prenatal diagnosis, and evaluate the risk of anti-αIIbβ3 immunization |
| Evaluation prior to pregnancy | |
| CBC (PLT, Hb, MCV), ferritinemia | To screen for anemia and iron deficiency |
| Previous history of PPH or other adverse pregnancy outcomes | To assess maternal and fetal/neonatal related risks |
| Recent platelets or RBC transfusion (<3-6 mo) | To assess the risk of recurrence or development of antiplatelet antibodies |
| Anti-HLA antibodies screening | To select treatment strategies, ensure efficacy, and anticipate tolerance of platelet concentrates administration |
| Anti-αIIbβ3 antibodies screening (MAIPA) | To select treatment strategies, ensure efficacy, and anticipate tolerance of platelet concentrates administration To evaluate the risk of fetal/neonatal thrombocytopenia |
| Oral and nasal clinical status | To assess needs and anticipate potential treatment needed to prevent further increase in gum- and nose-bleeding episodes during pregnancy |
| Fertility of couple | To evaluate the chances of obtaining pregnancy and avoid unnecessary exposure to heavy menstrual bleeding in case of infertility |
CBC, complete blood count; Hb, hemoglobin; MCV, mean corpuscular volume; PLT, platelet count; RBC, red blood cell.